|
|
|
16.07.25 - 13:09
|
Ionis to hold second quarter 2025 financial results webcast (Business Wire)
|
|
|
Webcast scheduled for Wednesday, July 30 at 11:30 a.m. Eastern TimeCARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 30th at 11:30 a.m. Eastern Time to discuss its second quarter 2025 financial results and progress on key programs.
The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.
About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a pa...
|
|
|
|
|
|
|
|
|
01.07.25 - 11:00
|
Ionis Pharmaceuticals: Spannender Ausblick (Sharedeals)
|
|
|
Das US-Biotechunternehmen Ionis Pharmaceuticals durchläuft derzeit eine hochspannende Phase. Ionis gilt als Pionier auf dem Gebiet der Antisense-Oligonukleotid-(ASO)-Technologie. In der Fachzeitschrift Nature werden ASOs als „unglaublich vielseitige Moleküle“ beschrieben, die gezielt RNA-Transkripte verändern können, um den Verlauf seltener genetischer Erkrankungen zu verlangsamen oder zu stoppen – sowohl auf Patienten- als auch auf Individualebene. Ionis hat […]
The post Ionis Pharmaceuticals: Spannender Ausblick first appeared on sharedeals.de....
|
|
|
12.06.25 - 15:06
|
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026 (Business Wire)
|
|
|
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief development officer, will retire effective January 2026 and that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed him in the role.
“Richard has made tremendous contributions to Ionis over his 30-year tenure during which he spearheaded dozens of development programs and brought six innovative medicines through regulatory approvals, including TRYNGOLZA, our first independent commercial medicine. We thank him for his leadership and unwavering dedication to patients in need,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “Holly is a deeply respected and innovative leader who will champion our vision to bring a steady cadence of transformational medicines to people in need and support Ionis' continued growth as a fully integrated biotechnology company. Her broad experience across research and developme...
|
|
|
|
|
06.05.25 - 13:06
|
Ionis to host 2025 virtual Annual Meeting of Stockholders (Business Wire)
|
|
|
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 5, 2025.
The agenda for the event is as follows:
5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders
All stockholders of record at the close of business on April 7, 2025, are invited to participate in the virtual Annual Meeting webcast, which will be broadcast live at www.virtualshareholdermeeting.com/IONS2025.
Stockholders of record will receive an official proxy card from their brokerage firm. Each proxy card contains a 16-digit control number required to log-in, vote and submit questions during the webcast
Ionis does not provide proxy cards or have access to proxy card information, including 16-digit control numbers. For help obtaining a proxy card, locating your control number or for instructions to access the webcast, stockholders...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.04.25 - 13:03
|
Ionis reports first quarter 2025 financial results (Business Wire)
|
|
|
- Encouraging start to first independent launch with TRYNGOLZATM -
- On track for second independent launch with donidalorsen PDUFA August 21, 2025 -
- Increasing 2025 financial guidance by more than 20% -
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results for the first quarter ended March 31, 2025.
“With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis' new chapter as a fully integrated, commercial-stage biotechnology company is well underway,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “We look forward to continued momentum this year, including our second independent launch for donidalorsen in hereditary angioedema and Phase 3 results for olezarsen for severe hypertriglyceridemia in the third quarter. We also continue to advance our next wave of wholly owned neurology medicines, including ...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
